WASHINGTON, DC (Reuters) – President Donald Trump announced plans to impose a 25% or higher tariff on semiconductor and pharmaceutical imports, a move that could significantly impact India’s ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

At Dr. David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments. But recently, another word is coming up just as often — generics. It is a ...

Novo Nordisk is leaning on clinical evidence, localised pricing and partnerships as its frontline defence in India’s brutal semaglutide price war unleashed after the Danish company’s patent expired on ...

Indian pharma majors Sun Pharma, Dr Reddy’s, Glenmark, and Zydus Lifesciences on Saturday announced the launch of their generic versions of semaglutide injections, used for diabetes and weight ...

India's pharma industry is ready to flex its generics muscle as the patent for a key ingredient of blockbuster weight-loss drugs expires today. Pharmarack estimates India’s weight-loss drug market to ...

Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET In this video The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant ...

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...

The FDA has approved a generic version of fluticasone propionate (marketed as Flovent HFA), according to a statement issued on March 3. The approval extends the accessibility of the medication, ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...